Nov 2026· Journal of Endovascular Therapy· pp.
15266028261502671
· 0 citations· 13 references
Medicine
TL;DR
BMS and CS showed no significant differences in TRAS outcomes, which suggests that covered stents may be a reasonable option when heavy calcification, a friable wall or mural thrombus raise concern for embolisation or rupture, while bare-metal stents remain appropriate for most lesions.
Abstract
Purpose
To compare short- and long-term outcomes of bare-metal (BMS) vs covered (CS) balloon-expandable stents in transplant renal artery stenosis (TRAS).
Materials And Methods
This retrospective study evaluated patients who underwent elective stent placement for TRAS between 2016 and 2023. Short-term efficacy was assessed by clinical improvement (resolution of resistant hypertension/hypervolemia) and reduction in serum creatinine (sCr) within 14 days post-procedure. Long-term outcomes included Doppler ultrasound parameters - peak systolic velocity (PSV), acceleration time (AT) and resistive index (RI) - and restenosis/occlusion rates requiring or not intervention. Graft survival at the latest follow-up was recorded.
Results
A total of 40 patients (mean age 58 ± 13 years, 68% male) were treated with BMS (n = 31) or CS (n = 9). Clinical improvement was observed in 71% of BMS and 83% of CS patients (P = 1.00). Median sCr decreased by 26% and 33% in BMS and CS patients, respectively (P = .30). At a median follow-up of 29 months, there were no statistically significant differences between groups in median PSV reduction (47% BMS vs 47% CS; P = .44), AT improvement (36% BMS vs 25% CS; P = .38) or RI increase (15% BMS vs 33% CS; P = .12). In the BMS group, 2 cases of in-stent restenosis occurred (6.5%). In the CS group, 1 stent occlusion occurred (11%), resulting in graft loss. At final follow-up, overall graft survival was 85%.
Conclusion
In this pilot study, BMS and CS showed no significant differences in TRAS outcomes. Further studies are warranted to better guide stent selection.Clinical ImpactIn transplant renal artery stenosis, balloon-expandable covered stents achieved clinical, biochemical and Doppler outcomes comparable to bare-metal stents, despite being used in more complex, atherosclerotic and longer lesions. This first direct comparison suggests that covered stents may be a reasonable option when heavy calcification, a friable wall or mural thrombus raise concern for embolisation or rupture, while bare-metal stents remain appropriate for most lesions. The single late covered-stent occlusion with graft loss highlights the need for careful platform selection and antiplatelet management. These pilot data should inform adequately powered multicentre registries rather than directly change practice.
Summary: Background: Inferior vena cava (IVC) obstruction may cause acute descending thrombosis, post-thrombotic syndrome, or chronic venous insufficiency. Endovascular IVC stent reconstruction may improve clinical outcomes but the risk of patency loss is considerable. Stent design might impact the patency rates, but d...
G. Forgo, S. Cardi, S. Wolf et al.· VASA. Zeitschrift fur Gefass...· 0 citations
Background: The global burden of end-stage renal disease (ESRD) continues to increase, leading to a growing demand for durable hemodialysis vascular access. Percutaneous transluminal angioplasty (PTA) remains the standard treatment for stenotic lesions within the dialysis access circuit; however, the comparative effect...
Elsayed Younes, Najib A. Alaskary, Ahmed O. Korany et al.· International Journal of Dru...· 0 citations
The long-term outcomes of patients with in-stent restenosis (ISR) presenting with Acute Coronary Syndrome (ACS) are not well studied. This study aims at investigating the outcomes of patients with drug-eluting stents (DES)-ISR presenting with ACS undergoing percutaneous coronary intervention (PCI) with DCB or thi...
R. Januszek, W. Wanha, F. D'Ascenzo et al.· European Heart Journal· 0 citations
AIM
Coronary artery calcification presents major challenges during PCI, including device deliverability, suboptimal lesion preparation, impaired stent expansion, increased restenosis, stent thrombosis and mortality. Drug-coated balloons (DCB) offer a stent-less alternative, but evidence in de novo calcified lesions is...
Rajkumar Natarajan, N. Corballis, I. Merinopoulos et al.· American Journal of Cardiolo...· 0 citations
Background In-stent restenosis (ISR) remains a major limitation after percutaneous coronary intervention (PCI) with drug-eluting stents (DESs). However, long-term patency data after chronic total occlusion (CTO) PCI are limited despite high ISR risk. We evaluated long-term ISR incidence and predictors after CTO PCI. Me...
Lauri Mansikkaniemi, Juhani A. Stewart, J. Sinisalo et al.· International Journal of Car...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.